# GLENMARK (GLENMARK) — Stock analysis

> Faxioms all-in-one stock review. Canonical page: https://faxioms.com/stocks/glenmark

## Current market snapshot

- Exchange: NSE
- Country: India
- Price: ₹2,410.9
- Change: -0.21%
- As of: 2026-09-18
- 1D return: +1.30%
- 5D return: +1.34%
- 1M return: +4.91%
- Latest complete quarter: fy27_q1

## Faxioms Analysis

_As of 2026-09-18_

### Technical Outlook

As of September 18, 2026, GLENMARK's stock is trading at ₹2447.4, showing a mixed technical picture across different timeframes. Daily and weekly charts indicate a bullish trend, with the price trading above key moving averages like the 20-day EMA (₹2410.22) and 20-week EMA (₹2302.2), and the Supertrend indicator signaling bullishness on both timeframes. However, the monthly timeframe presents a conflicting signal, with the Supertrend indicator in a bearish direction and the price below it, despite trading above the 20-month EMA (₹2049.74). The stock is currently positioned in the upper half of its recent trading range, approximately 88% of the way up its 252-day range.

Nearest support is observed around ₹2435.6, followed by ₹2425.8. Resistance is noted at ₹2454.3, with further levels at ₹2483.0 and ₹2537.6. The stock exhibits an annualized volatility of 30% and has experienced a current drawdown of -3%. Key patterns observed include an active Inside Bar on the monthly chart and a Hammer pattern on the weekly chart as of September 18, 2026.

Key watch conditions include monitoring the price action around the nearest resistance level of ₹2454.3. A sustained move above this level could strengthen the bullish short-to-medium term outlook. Conversely, a break below the support level of ₹2425.8, especially with increased volume, could signal further weakness, potentially aligning with the bearish monthly trend signal.

- Stock closed at ₹2447.4 on September 18, 2026.
- Daily and weekly timeframes show bullish trends, with prices above key moving averages and Supertrend.
- Monthly timeframe shows a bearish Supertrend signal, contrasting with shorter timeframes.
- Nearest support levels are ₹2435.6 and ₹2425.8.
- Nearest resistance level is ₹2454.3.
- Annualized volatility is 30% with a current drawdown of -3%.

- Inside Bar
- Hammer
- Harami
- Bearish Engulfing Reversal
- Doji

### What Changed

Glenmark Pharmaceuticals (NSE: GLENMARK) saw its stock price increase to ₹2447.4 on September 18, 2026, from ₹2416.0 on the previous trading day. The available evidence does not indicate any new filings or news developments for the company as of the report date. The company's profile and listing on the NSE remain unchanged from the prior context.

- Stock price rose to ₹2447.4 on September 18, 2026, from ₹2416.0 on the previous trading day.
- No new filings or news developments were reported as of September 18, 2026.
- The company continues to be listed on the NSE.

### Official Filings

Glenmark Pharmaceuticals has seen significant developments in its credit rating and product launches. On September 11, 2026, India Ratings and Research upgraded the company's long-term bank loans to 'IND AA+' with a Stable Outlook, citing recognition of USD560 million in revenue from a July 2025 licensing agreement with AbbVie Inc. This revenue recognition contributed to Glenmark achieving zero gross debt by the fiscal year ended March 31, 2026. Concurrently, the company announced the launch of its RYALTRIS® Nasal Spray in Brazil on September 11, 2026, expanding its global respiratory product reach. In the United States, Glenmark Pharmaceuticals Inc., USA, launched Calcium Gluconate Injection USP on August 21, 2026, targeting a market segment with approximately $69.9 million in annual sales for the 12 months ending June 2026. Additionally, the company received U.S. FDA approval on August 20, 2026, for Fluticasone Propionate Nasal Spray USP, a product whose reference drug achieved approximately $295.2 million in annual sales for the 12 months ending June 2026. Glenmark also settled three antitrust complaints for $15.28 million on August 11, 2026, a payment fully provided for in its financials without admission of liability or significant impact on its financial position. The company's 48th Annual General Meeting was held on September 11, 2026, where shareholders approved financial statements, declared a dividend of INR 2.50 per equity share, and re-appointed a Non-Executive Director, with all resolutions passing with over 95% approval.

- On September 11, 2026, India Ratings and Research upgraded Glenmark Pharmaceuticals Ltd's long-term bank loans to 'IND AA+' with a Stable Outlook.
- Glenmark Pharmaceuticals announced the launch of RYALTRIS® Nasal Spray in Brazil on September 11, 2026.
- Glenmark Pharmaceuticals Inc., USA, launched Calcium Gluconate Injection USP on August 21, 2026, in the U.S.
- The company received U.S. FDA approval for Fluticasone Propionate Nasal Spray USP on August 20, 2026.
- Glenmark Pharmaceuticals Inc. USA agreed to a settlement of $15.28 million on August 11, 2026, to resolve antitrust complaints.
- The 48th Annual General Meeting was held on September 11, 2026, approving financial statements and a dividend of INR 2.50 per equity share.

- Glenmark Pharmaceuticals Limited has informed the Exchange about Credit Rating |SUBJECT: Credit Rating
- Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated September 11, 2026, titled "Glenmark Expands Global Respiratory Innovation Footprint with RYALTRIS® Launch in Brazil ". |SUBJECT: Press Release
- Glenmark Pharmaceuticals Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 11, 2026. Further, the company has submitted the Exchange a copy of Srutinizers report along with voting results. |SUBJECT: Shareholders meeting
- MEETING DATE : 11-SEP-2026
- Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated August 21, 2026, titled "Glenmark Pharmaceuticals Inc., USA launches Calcium Gluconate Injection USP, 1,000 mg/10 mL (100 mg/mL), 5,000 mg/50 mL (100 mg/mL) Single-Dose Vials and 10,000 mg/100 mL (100 mg/mL) Pharmacy Bulk Package". |SUBJECT: Press Release
- Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated August 20, 2026, titled "Glenmark Pharmaceuticals receives U.S. FDA approval for Fluticasone Propionate Nasal Spray, 0.05 mg (50 mcg)/spray". |SUBJECT: Press Release
- Glenmark Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication |SUBJECT: Copy of Newspaper Publication
- Letter to shareholders whose email address are not registered providing the Web Link of Integrated Annual Report |SUBJECT: General Updates
- Glenmark Pharmaceuticals Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 11, 2026 |SUBJECT: Shareholders meeting
- Settlement Agreement - Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 |SUBJECT: General Updates

### Fundamentals

Glenmark Pharmaceuticals reported revenue from operations of ₹4,018.48 crore for Q1 FY2026-27. This represents a sequential increase from ₹3,770.59 crore in Q4 FY2025-26 and ₹3,900.62 crore in Q3 FY2025-26.

Profit Before Exceptional Items and Tax was ₹643.39 crore in Q1 FY2026-27. This is higher than ₹761.17 crore in Q4 FY2025-26 but lower than ₹718.34 crore in Q3 FY2025-26. Profit Before Tax also stood at ₹643.39 crore for Q1 FY2026-27, an increase from ₹387.77 crore in Q4 FY2025-26 and ₹534 crore in Q3 FY2025-26. The company reported a Tax Expense of ₹160.56 crore for Q1 FY2026-27.

Finance Costs increased to ₹54 crore in Q1 FY2026-27 from ₹42.60 crore in Q4 FY2025-26 and ₹41.43 crore in Q3 FY2025-26. Other Expenses also saw an upward trend, reaching ₹1,033.19 crore in Q1 FY2026-27 compared to ₹948.27 crore in Q4 FY2025-26 and ₹894.37 crore in Q3 FY2025-26. Investors may want to monitor the trend in finance costs and other expenses in relation to revenue growth.

- Revenue from operations for Q1 FY2026-27 was ₹4,018.48 crore.
- Profit Before Exceptional Items and Tax for Q1 FY2026-27 was ₹643.39 crore.
- Profit Before Tax for Q1 FY2026-27 was ₹643.39 crore.
- Finance Costs increased to ₹54 crore in Q1 FY2026-27.
- Other Expenses increased to ₹1,033.19 crore in Q1 FY2026-27.

### Bull Case

Glenmark Pharmaceuticals' stock shows constructive signals across multiple technical timeframes as of September 18, 2026. The daily trend indicates bullish momentum, with the closing price of ₹2447.4 exceeding both the 20-day Exponential Moving Average (EMA) of ₹2410.22 and the 50-day EMA of ₹2351.68. The Supertrend indicator is also in a bullish direction. This positive trend extends to the weekly timeframe, where the closing price is above the 20-day EMA (₹2302.22) and 50-day EMA (₹2158.69), with a bullish Supertrend signal. The stock has also demonstrated significant positive returns over various periods, including a 16% return over the last year and a 21% year-to-date return. However, the monthly trend shows a bearish Supertrend direction, suggesting caution is warranted despite the shorter-term positive indicators.

- As of September 18, 2026, the daily Supertrend indicator for Glenmark Pharmaceuticals is bullish.
- The stock's closing price of ₹2447.4 on September 18, 2026, is above its 20-day EMA (₹2410.22) and 50-day EMA (₹2351.68) on the daily chart.
- Glenmark Pharmaceuticals has achieved a 16% return over the past year and a 21% year-to-date return.
- The weekly trend shows a bullish Supertrend direction and the closing price is above the 20-day EMA (₹2302.22) and 50-day EMA (₹2158.69).

- Domestic pharma market sustains growth momentum, but margins remain key

### Bear Case

The company's monthly trend indicators suggest a bearish setup, with the Supertrend indicator at ₹2665.43 and an ADX of 59.73, indicating strong bearish momentum. While the daily trend shows a bullish Supertrend at ₹2299.3, the monthly view presents a cautionary signal regarding sustained performance. The company has experienced a maximum drawdown of -22% and a current drawdown of -3%, indicating past significant price declines and recent downward pressure.

- Monthly trend analysis shows a bearish Supertrend at ₹2665.43 with a high ADX of 59.73 as of 2026-09-18.
- The company has experienced a maximum drawdown of -22%.
- The current drawdown stands at -3% as of 2026-09-18.

- Domestic pharma market sustains growth momentum, but margins remain key

### FAQs

**What is the recent credit rating update for Glenmark Pharmaceuticals and its implications?**

On September 10, 2026, India Ratings and Research upgraded Glenmark Pharmaceuticals Ltd's long-term bank loans to 'IND AA+' with a Stable Outlook, from 'IND AA'. Short-term loans were affirmed at 'IND A1+'. This upgrade was influenced by the company's recognition of USD560 million in revenue from a July 2025 licensing agreement with AbbVie Inc., which contributed to Glenmark achieving zero gross debt by the fiscal year ended March 31, 2026. The agency also assigned ratings to new bank loan facilities totaling INR42 billion.

**What new product launches has Glenmark announced recently, and in which markets?**

Glenmark announced the commercial launch of RYALTRIS® Nasal Spray in Brazil on September 11, 2026, for treating moderate to severe allergic rhinitis. This product, already approved in 57 global markets, is the first olopatadine-containing intranasal combination therapy available in Brazil. Additionally, Glenmark Pharmaceuticals Inc., USA, launched Calcium Gluconate Injection USP in multiple presentations on August 21, 2026. The US market for these presentations achieved annual sales of approximately $69.9 million for the 12 months ending June 2026.

**What were the key outcomes of Glenmark's 48th Annual General Meeting held on September 11, 2026?**

During the AGM on September 11, 2026, shareholders approved the financial statements for the fiscal year ended March 31, 2026, and declared a dividend of INR 2.50 per equity share. Mrs. Blanche Saldanha was re-appointed as a Non-Executive Director, and the remuneration for the Cost Auditor for the year ending March 31, 2027, was ratified. All resolutions passed with over 95% approval.

**How has Glenmark's stock performed over different periods leading up to September 18, 2026?**

As of September 18, 2026, Glenmark's stock has shown positive returns over several periods. Year-to-date, the return was 0.21. Over the last 3 months, the return was 0.14, and over the last 6 months, it was 0.12. The stock also saw a return of 0.16 over the last year and 0.52 since the start of its trading history.

**What do the technical indicators suggest about Glenmark's stock trend as of September 18, 2026?**

On a daily basis, technical indicators suggest a bullish trend, with the Supertrend indicator at 2299.3 and the 20-day Exponential Moving Average (EMA) at 2410.22, showing upward momentum. However, the monthly trend analysis indicates a bearish direction, with the Supertrend at 2,665.43 and a high ADX value of 59.73, suggesting strong but potentially volatile market conditions.

- Domestic pharma market sustains growth momentum, but margins remain key
- Glenmark Pharmaceuticals Limited has informed the Exchange about Credit Rating |SUBJECT: Credit Rating
- Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated September 11, 2026, titled "Glenmark Expands Global Respiratory Innovation Footprint with RYALTRIS® Launch in Brazil ". |SUBJECT: Press Release
- Glenmark Pharmaceuticals Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 11, 2026. Further, the company has submitted the Exchange a copy of Srutinizers report along with voting results. |SUBJECT: Shareholders meeting
- MEETING DATE : 11-SEP-2026
- Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated August 21, 2026, titled "Glenmark Pharmaceuticals Inc., USA launches Calcium Gluconate Injection USP, 1,000 mg/10 mL (100 mg/mL), 5,000 mg/50 mL (100 mg/mL) Single-Dose Vials and 10,000 mg/100 mL (100 mg/mL) Pharmacy Bulk Package". |SUBJECT: Press Release
## Technical analytics

- As of: 2026-09-18
- Daily trend: Strong Uptrend
- Weekly trend: Moderate Uptrend
- Pivot point: ₹2,407.1
- Risk regime: Price Risk Currently Contained

### Support levels
- 2204.8
- 2115.1
- 2019.6865234375

### Resistance levels
- 2483
- 2537.6
- 2454.2999999999997

### Return and range metrics

| Metric | Value |
| --- | --- |
| return_1 | +1.30% |
| return_10 | -0.47% |
| return_1m | +6.18% |
| return_1y | +16.08% |
| return_20 | +4.91% |
| return_3m | +13.62% |
| return_5 | +1.34% |
| return_6m | +11.94% |
| return_since_start | +51.59% |
| return_ytd | +20.79% |

### Risk and volatility metrics

| Metric | Value |
| --- | --- |
| state | contained_risk |
| label | Price risk currently contained |
| summary | Recent drawdown and price variability remain within the producer's contained-risk thresholds. |
| maximum_drawdown | -22.11% |
| annualized_volatility | +30.35% |

## Quarterly financials

- Latest complete quarter: fy27_q1

# Revenue rises 23% year over year while reported profit surges, though sequential profitability declines as costs outpace sales

Glenmark Pharmaceuticals reported revenue of ₹4,018.48 crore for the quarter ended 30 June 2026 (FY2026-27 Q1), a 23% increase from the same period last year. Reported net profit climbed to ₹482.83 crore, driven largely by the absence of large pre-tax charges that reduced earnings in the prior year. Underlying profit before exceptional items grew 54% year over year. On a sequential basis, revenue increased modestly, but underlying profitability fell as total expenses rose faster than top-line income.

## Revenue Performance

Revenue from operations for the quarter ended 30 June 2026 stood at ₹4,018.48 crore. This represents a 6.57% increase from the preceding quarter (March 2026) and a 23.1% increase from the year-ago quarter (June 2025). 

Over the five available quarters, the September 2025 period stands as a distinct outlier with revenue of ₹6,046.87 crore, approximately 50% higher than the current quarter. Excluding that single period, the current quarter reflects the highest revenue level recorded in the series. The sequence has moved from ₹3,264.44 crore in June 2025, spiked to ₹6,046.87 crore in September 2025, settled around ₹3,770–₹3,900 crore in late 2025, and returned to ₹4,018.48 crore in the current quarter.

## Profitability and Exceptional Items

Financial results show a clear divergence between underlying operating performance and reported pre-tax profit due to non-recurring items.

Underlying profit before exceptional items and tax (PBEIT) increased to ₹643.39 crore in the current quarter. Compared to the year-ago quarter, this represents a 53.6% increase. However, compared to the immediately preceding quarter, PBEIT decreased by 15.5% from ₹761.17 crore.

In the current quarter, reported profit before tax (PBT) matched PBEIT at ₹643.39 crore, indicating no exceptional items were recognized below the pre-exceptional line. In contrast, the year-ago quarter showed a significant gap: PBEIT was ₹418.81 crore while PBT was only ₹95.58 crore. This difference of ₹323.23 crore reflects substantial exceptional charges deducted in the prior year.

The reported 573% year-over-year increase in PBT is therefore amplified by the removal of these prior-year charges. The increase in underlying profit contributed ₹224.6 crore to the total growth, while the reduction in the exceptional-item gap contributed ₹323.2 crore, together accounting for the full ₹547.8 crore increase in reported PBT.

## Expense Trends and Sequential Margin Pressure

While revenue and total income both grew sequentially, underlying profitability declined, indicating that total costs expanded faster than top-line sales.

Other expenses increased by 8.96% quarter-on-quarter to ₹1,033.19 crore, outpacing the 6.57% revenue growth. Finance costs rose by 26.74% to ₹54 crore, though the absolute amount remains small relative to revenue.

Total income (revenue plus other income) grew by ₹124.58 crore sequentially, rising from ₹3,959.67 crore to ₹4,084.25 crore. Despite this income growth, PBEIT fell by ₹117.78 crore. The combined increase in other expenses and finance costs accounts for only a portion of this profit decline, meaning other operating costs also rose during the period. The sequential drop in underlying profit highlights that cost expansion exceeded revenue gains.

## Tax, Net Profit, and Comprehensive Income

Tax expense for the quarter was ₹160.56 crore, an 85.7% increase from the preceding quarter and a 230% increase from the year-ago quarter. The effective tax rate on reported pre-tax profit was approximately 25% (₹160.56 crore divided by ₹643.39 crore). This aligns closely with the rates observed in the third and fourth quarters of the prior fiscal year (approximately 24.5% and 22.3%), though it is higher than the rate calculated on the depressed pre-tax profit of the year-ago quarter.

Net profit from continuing operations reached ₹482.83 crore, up 60.2% from the March quarter and 927.9% from the year-ago quarter. Basic and diluted earnings per share were both ₹17.11. Dividing net profit by basic earnings per share yields an implied share count of approximately 28.2 crore, which remains stable across the reported periods.

Comprehensive income for the period was ₹523.28 crore, exceeding net profit by ₹40.45 crore. This pattern—where comprehensive income exceeds net profit—has persisted across all five quarters shown, indicating consistent positive other comprehensive income. The magnitude of this addition was lower in the current quarter compared to the March quarter, where the gap was nearly ₹189 crore.

## Key Takeaway

The quarter delivered substantially higher earnings than the same period last year, with revenue growing 23% and net profit surging nearly tenfold. However, the headline profit growth is amplified by the fact that the prior year included large pre-tax charges that are absent this year. When looking at underlying profit before exceptional items, growth was more moderate at 54% year over year. Sequentially, the company generated more revenue but less underlying profit, as expenses grew faster than sales during the quarter.

### Ratios

## Official filings

- 2026-09-11 — Credit Rating Update: Glenmark Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/GLENMARK_11092026084352_BSE_NSE_IndiaRatings_Signed.pdf)
- 2026-09-11 — Press Release: Glenmark Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/GLENMARK_11092026085036_Press_Release_11092026_Signed.pdf)
- 2026-09-11 — Generic Announcement: Glenmark Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/GLENMARK_11092026185249_AGMOutcome.pdf)
- 2026-09-11 — Regulatory Filing: Glenmark Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/RESULT_VOTING_1723766_11092026065545_WEB.xml)
- 2026-08-21 — Press Release: Glenmark Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/GLENMARK_21082026084736_Press_Release_21082026_Signed.pdf)
- 2026-08-20 — Press Release: Glenmark Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/GLENMARK_20082026084458_Press_Release_20282026_Signed.pdf)
- 2026-08-15 — Generic Announcement: Glenmark Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/GLENMARK_15082026183615_NSE_BSE_Newspaper_Publication_signed.pdf)
- 2026-08-13 — Generic Announcement: Glenmark Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/GLENMARK_13082026213345_SE_LettertoSH_signed.pdf)
- 2026-08-13 — Generic Announcement: Glenmark Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/GLENMARK_13082026195442_SE_AGM2526_signed.pdf)
- 2026-08-11 — Litigation Disclosure: Glenmark Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/GLENMARK_11082026223237_Humana_Intimation_11082026_signed.pdf)
- 2026-08-10 — Generic Announcement: Glenmark Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/GLENMARK_10082026145726_SE_ESOPAllotment_Signed.pdf)
- 2026-08-10 — Generic Announcement: Glenmark Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/ALTERATION_OF_CAPITAL_AND_FUND_RAISING_1853_WebXMLFile_20260810_151907081.xml)
- 2026-08-07 — Generic Announcement: Glenmark Pharmaceuticals Limited announced its 48th Annual General Meeting will be held on September 11, 2026, at 2:00 p.m. via Video Conferencing/Other Audio-Visual Means. The dividend record date is August 31, 2026, and remote e-voting will be open from September 8 to September 10, 2026. Public notices were published in the Financial Express and Loksatta on August 7, 2026. — [Official attachment](https://nsearchives.nseindia.com/corporate/GLENMARK_07082026125803_NSE_BSE_Newspaper_Publication_Signed.pdf)
- 2026-08-07 — Generic Announcement: Glenmark Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_1853_WebXMLFile_20260807_161205559.xml)
- 2026-08-07 — Generic Announcement: Glenmark Pharmaceuticals Limited will participate in analyst and institutional investor meetings scheduled for August 12, 2026 (Emkay Confluence 2026), August 17, 2026 (Motilal Oswal 22nd Annual Investor Conference 2026), September 1, 2026 (Elara India Dialogue 2026), and September 17, 2026 (Kotak Healthcare Forum). The company will not disclose any Unpublished Price Sensitive Information (UPSI) during these meetings. — [Official attachment](https://nsearchives.nseindia.com/corporate/GLENMARK_07082026144853_SE_Investor_Meet_Signed.pdf)
- 2026-08-05 — Generic Announcement: Glenmark Pharmaceuticals Limited has uploaded the transcript of its earnings call held on August 3, 2026, for the quarter ended June 30, 2026. This disclosure was made on August 5, 2026, in compliance with SEBI (LODR) Regulations, 2015. — [Official attachment](https://nsearchives.nseindia.com/corporate/GLENMARK_05082026155153_BSE_NSE_EarningCallsTranscript_Signed.pdf)
- 2026-08-05 — Generic Announcement: Glenmark Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_1853_WebXMLFile_20260805_161059185.xml)
- 2026-08-03 — Generic Announcement: Glenmark Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_1853_WebXMLFile_20260803_163342094.xml)
- 2026-08-03 — Generic Announcement: Glenmark Pharmaceuticals Limited uploaded an audio recording of its Q1 FY 2026-27 Earnings Call, held on August 03, 2026, to the company's website as per SEBI regulations. The recording is available at https://glenmark.b-cdn.net/gpl_pdfs/Financials/Quarterly/Q1%20FY27%20Earnings%20Call%20recording.mp3. — [Official attachment](https://nsearchives.nseindia.com/corporate/GLENMARK_03082026161611_BSE_NSE_EARNINGCALL_Recording_signed.pdf)
- 2026-08-01 — Generic Announcement: Glenmark Pharmaceuticals Limited announced the approval and publication of its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The results were approved by the Board of Directors on July 31, 2026, and published in the Financial Express and Loksatta newspapers on August 1, 2026. The company's website also features this information. — [Official attachment](https://nsearchives.nseindia.com/corporate/GLENMARK_01082026145340_BSE_NSE_Covering_signed.pdf)
- 2026-07-31 — Generic Announcement: On July 31, 2026, Glenmark Pharmaceuticals Limited's Board of Directors approved amendments to the Policy on Determination of Materiality for Disclosures. The company also updated its list of authorized officials for making disclosures to stock exchanges, including Glenn Saldanha (Chairman & Managing Director), Cherylann Pinto (Executive Director – Corporate Services), Anurag Mantri (Executive Director & Global Chief Financial Officer), and Rashmi Khandelwal (Company Secretary & Compliance Officer). — [Official attachment](https://nsearchives.nseindia.com/corporate/GLENMARK_31072026190222_BSE_NSE_Materiality_Policy_signed.pdf)
- 2026-07-31 — Earnings Presentation: Glenmark Pharmaceuticals Limited reported consolidated revenue of Rs. 40,185 million for Q1 FY27, a 23.1% year-over-year increase. The company's India business grew 15.5%, North America core business by 19.8%, EU business by 11.9%, and Emerging Markets by 27.7%. Consolidated R&D expenses were Rs. 2,494 million, EBITDA was Rs. 8,048 million with a 20.03% margin, and Profit After Tax (PAT) was Rs. 4,828 million with an 11.8% margin. — [Official attachment](https://nsearchives.nseindia.com/corporate/GLENMARK_31072026191907_SE_Investor_Presentation_31072026_signed.pdf)
- 2026-07-31 — Generic Announcement: Glenmark Pharmaceuticals' Board approved unaudited financial results for the quarter ended June 30, 2026, and set the 48th AGM for September 11, 2026, with a record date of August 31, 2026. The Board also approved amendments to several policies and reconstituted the Risk Management Committee, effective August 1, 2026. The company reported standalone net sales of ₹23,425.26 million and consolidated net sales of ₹39,317.30 million for the quarter. — [Official attachment](https://nsearchives.nseindia.com/corporate/GLENMARK_31072026185223_BSE_NSE_Results_31072026_signed.pdf)
- 2026-07-31 — Press Release: Glenmark Pharmaceuticals announced its financial results for the first quarter ended June 30, 2026, reporting a consolidated revenue of Rs. 40,185 million, a 23.1% increase year-over-year. The company's EBITDA grew by 38.6% to Rs. 8,048 million, and Profit After Tax (PAT) was Rs. 4,828 million. Key growth drivers included a 15.5% increase in India Formulations revenue and a 41.1% rise in North America revenue, which included deferred out-licensing income recognition for ISB 2001. — [Official attachment](https://nsearchives.nseindia.com/corporate/GLENMARK_31072026191156_SE_PR_MDA_signed.pdf)
- 2026-07-31 — Generic Announcement: Glenmark Pharmaceuticals' Board approved unaudited financial results for the quarter ended June 30, 2026, and set the 48th AGM for September 11, 2026, with a record date of August 31, 2026. The Board also approved amendments to several policies and reconstituted the Risk Management Committee, effective August 1, 2026. The company reported standalone net sales of ₹23,425.26 million and consolidated net sales of ₹39,317.30 million for the quarter. — [Official attachment](https://nsearchives.nseindia.com/corporate/GLENMARK_31072026183412_BSE_NSE_Results_31072026_signed.pdf)

## News and market events

- 2026-09-16 — Mint: **Domestic pharma market sustains growth momentum, but margins remain key** — Domestic pharma growth remained strong in August, led by price hikes and new launches, but weak volumes and US tariff uncertainty mean a sustained margin recovery will be crucial for sector performance. — [Source](https://www.livemint.com/market/mark-to-market/indian-pharma-market-ipm-pharma-stocks-domestic-pharma-dr-reddy-s-laboratories-sun-pharma-ajanta-pharma-glenmark-11789538290089.html)
- 2026-09-11 — The Hindu: **Glenmark launches allergic rhinitis nasal spray RYALTRIS in Brazil** — Glenmark launches RYALTRIS nasal spray in Brazil, offering a dual-action treatment for allergic rhinitis after ANVISA approval. — [Source](https://www.thehindubusinessline.com/companies/glenmark-launches-allergic-rhinitis-nasal-spray-ryaltris-in-brazil/article71454792.ece)
- 2026-09-11 — BUSINESS: **Glenmark launches RYALTRIS Nasal Spray in Brazil** — Glenmark Specialty S.A., a wholly owned subsidiary of Glenmark Pharmaceuticals (Glenmark), today announced the launch of RYALTRIS Nasal Spray in Brazil for the treatment of moderate to severe symptoms associated with allergic rhinitis (AR) in adults and adolescents of 12 years of age and older. — [Source](https://www.business-standard.com/markets/capital-market-news/glenmark-launches-ryaltris-nasal-spray-in-brazil-126091100150_1.html)
- 2026-09-11 — The Hindu: **Stock Market Today Highlights, Sept 11: Sensex down 120 pts, Nifty closes at 23,398, logs 5th weekly loss as oil fears grip markets** — Sensex Today, Nifty 50 | Stock Market Highlights - Find here all the highlights related to Sensex, Nifty, BSE, NSE, share prices and Indian stock markets for 11 September 2026 — [Source](https://www.thehindubusinessline.com/markets/sensex-nifty50-today-stock-market-highlights-11th-september-2026/article71453005.ece)
- 2026-09-03 — Times of India: **Top stocks to buy today: Stock recommendations for September 3, 2026 - check list** — India Business News: Top stock market recommendations: Bank of Maharashtra, Glenmark Pharma, and Tata Technologies have been shared as the top stocks to buy today on Septe. — [Source](https://timesofindia.indiatimes.com/business/india-business/top-stock-recommendations-for-september-03-2026-bank-of-maharashtra-glenmark-pharma-tata-technologies-best-stocks-to-buy-today/articleshow/133723261.cms)
- 2026-08-21 — BUSINESS: **Nifty above 24,200 level; realty shares in demand** — At 12:30 IST, the barometer index, the S&P BSE Sensex gained 48.27 points or 0.06% to 77,585.99. The Nifty 50 index jumped 13.45 points or 0.05% to 24,244.55. — [Source](https://www.business-standard.com/markets/capital-market-news/nifty-above-24-200-level-realty-shares-in-demand-126082100525_1.html)
- 2026-08-21 — MONEYCONTROL: **Trade Spotlight: How should you trade Sai Life Sciences, EID Parry, Raymond, Glenmark Pharma, MCX India, and others on August 21?** — Trade Spotlight, Buy Ideas,Top Buy Ideas,Top Picks,Stock Picks,Top Stock Picks,Share Tips,Share Market Tips,Stock Tips,Stock Market Tips,Sai Life Sciences,Shriram Finance,EID Parry (India),Raymond,Glenmark Pharmaceuticals,Multi Commodity Exchange of India, — [Source](https://www.moneycontrol.com/news/business/markets/trade-spotlight-how-should-you-trade-sai-life-sciences-eid-parry-raymond-glenmark-pharma-mcx-india-and-others-on-august-21-14011993.html)
- 2026-08-20 — BUSINESS: **Nifty breaks losing streak, Sensex rallies 628 points; sugar stocks shine** — Key equity benchmarks staged a strong rebound on Thursday, with the Nifty snapping a seven-session losing streak and reclaiming the 24,200 level, while the Sensex jumped over 600 points. The recovery was supported by easing US Treasury yields after the US Treasury announced plans to double its buybacks of longer-duration government debt, helping steady global bond markets and improve risk appetite. Buying was broad-based, led by IT, financials, realty and media stocks, while the broader market also ended higher. The rupee snapped its three-day losing streak and closed at 95.71 per dollar. Technically, the Nifty faces an immediate hurdle at 24,290-24,320, while 24,130-24,100 remains a crucial support zone. — [Source](https://www.business-standard.com/markets/capital-market-news/nifty-breaks-losing-streak-sensex-rallies-628-points-sugar-stocks-shine-126082000932_1.html)
- 2026-08-20 — MONEYCONTROL: **Taking Stock: Nifty snaps 7-day losing streak, reclaims 24,200, Sensex jumps 628 pts** — Taking Stock,Sensex,Nifty,Local markets — [Source](https://www.moneycontrol.com/news/business/markets/taking-stock-nifty-snaps-7-day-losing-streak-reclaims-24-200-sensex-jumps-628-pts-14011339.html)
- 2026-08-20 — MONEYCONTROL: **Buzzing Stocks: United Spirits gains after FSSAI revokes order; Glenmark rises on USFDA approval** — Buzzing Stocks — [Source](https://www.moneycontrol.com/news/business/markets/buzzing-stocks-united-spirits-gains-after-fssai-revokes-order-glenmark-rises-on-usfda-approval-14010862.html)
- 2026-08-20 — MONEYCONTROL: **Glenmark Pharmaceuticals gains 1.4% after US FDA nod for Fluticasone nasal spray** — Glenmark Pharmaceuticals, Glenmark Pharmaceuticals news, Glenmark Pharmaceuticals shares, Glenmark Pharmaceuticals stocks, Glenmark Pharmaceuticals share price, Glenmark Pharmaceuticals US FDA — [Source](https://www.moneycontrol.com/news/business/stocks/glenmark-pharmaceuticals-gains-1-4-after-us-fda-nod-for-fluticasone-nasal-spray-14010963.html)
- 2026-08-17 — BUSINESSTODAY: **Top midcap stock picks for solid short-term gains: Check target prices, stop loss & upside** — Stocks to buy, Stock picks, Stocks to trade, trading views, Punjab National Bank, PNB, Swiggy, Glenmark Pharmaceuticals, PNB shares, Swiggy shares, Glenmark Pharma shares, PNB share price, Swiggy share price, Glenmark Pharma share price, PNB stock price, Swiggy stock price, Glenmark Pharma stock price, PNB target price, Swiggy target price, Glenmark Pharma target price — [Source](https://www.businesstoday.in/markets/stocks/story/pnb-swiggy-glenmark-pharma-top-midcap-stock-picks-for-solid-short-term-gains-check-target-prices-stop-loss-upside-549537-2026-08-17)
- 2026-08-10 — Economic Times: **Independence Day 2026: India, which once couldn't make smallpox vaccine, has now crossed a pharma milestone the world can't ignore** — 2026 Independence Day: India's pharmaceutical industry marks a historic milestone with a new drug approval. This achievement reflects decades of growth from importing medicines to global leadership. The nation now supplies a significant portion of the world's generic medicines and vaccines. The Covid-19 pandemic further showcased the industry's manufacturing capabilities globally. Government initiatives now aim to foster innovation and high-value biopharmaceutical production. — [Source](https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/independence-day-2026-india-pharma-journey-covaxin-made-in-india-drug-discovery-zaynich-wockhardt-ipa-indian-medicine-vaccine/articleshow/133003617.cms)
- 2026-08-10 — MONEYCONTROL: **Trade Spotlight: How should you trade Uno Minda, Glenmark Pharma, APL Apollo Tubes, Grasim Industries, TCS, and others on August 10?** — Trade Spotlight, Buy Ideas,Top Buy Ideas,Top Picks,Stock Picks,Top Stock Picks,Share Tips,Share Market Tips,Stock Tips,Stock Market Tips,Uno Minda,Glenmark Pharmaceuticals,APL Apollo Tubes,BLS International Services,Concord Biotech,Grasim Industries,Vedanta,Tata Consultancy Services — [Source](https://www.moneycontrol.com/news/business/markets/trade-spotlight-how-should-you-trade-uno-minda-glenmark-pharma-apl-apollo-tubes-grasim-industries-tcs-and-others-on-august-10-13999267.html)
- 2026-08-05 — CNBC-TV18: **Q1 Results LIVE Updates: Nykaa shares fall 3%, PNB Housing up 5%; Power Grid, Biocon report today** — Q1 Results LIVE Updates: Power Grid, Biocon, Aurobindo Pharma, Berger Paints, Allcargo Logistics, Aster DM, Bayer Corp, Bikaji, Cummins India, Datamatics, eClerx, GMM Pfaudler, GNFC, Godrej Agrovet, GE Vernova, JK Lakshmi Cement, Navin Fluorine, PB Fintech, Shree Renuka Sugar, Shilpa Medicare, Snowman Logistics, Whirlpool of India, are among the companies reporting their first quarter earnings today. Earnings reactions also come from stocks like BSE, MCX, ONGC, Bharti Airtel, Marico, Nykaa and many others. Watch this space for all the LIVE result updates. — [Source](https://www.cnbctv18.com/market/q1-results-live-updates-bharti-airtel-ongc-marico-nykaa-aurobindo-biocon-cummins-ge-vernova-pb-fintech-gnfc-whirlpool-berger-bse-mcx-share-price-liveblog-19961894.htm)
- 2026-08-04 — CNBC-TV18: **Sensex Today | Stock Market Live Updates: Sharp price divergence in Nifty, Sensex; LIC shares down 9%** — Stock Market LIVE Updates: Today's session is not only the weekly options expiry session for the Nifty 50 contracts, but is also set to see supply of paper worth nearly ₹36,000 crore, which includes the mega LIC Offer for Sale (OFS). Earnings season is drawing to a close and therefore, companies are making a beeline to report numbers as well. Adding to that is the confusion surrounding the Closing Auction Session. Watch this space for all the LIVE stock market updates. — [Source](https://www.cnbctv18.com/market/stock-market-live-updates-sensex-nifty-50-today-banks-midcaps-lic-paytm-meesho-kalyan-arvind-bharti-bse-share-price-liveblog-19960944.htm)
- 2026-08-02 — CNBC-TV18: **Stocks to Watch for August 3: Auto stocks, ITC, Maruti Suzuki, Indian Oil and more** — Markets will keep an eye on key earnings, auto sales updates and fresh order wins. Stocks in focus include Aarti Drugs, ITC, Maruti Suzuki, Indian Oil, Hero MotoCorp, Tata Motors and Mahindra & Mahindra after their quarterly results and July sales updates. Glenmark Pharma, ABB India, Blue Dart Express, NCC and Powerica will also be tracked for their earnings, order wins and business developments. — [Source](https://www.cnbctv18.com/photos/market/stocks-to-watch-for-august-3-auto-stocks-itc-maruti-suzuki-indian-oil-share-price-19959259.htm)
- 2026-07-31 — CNBC-TV18: **Q1 Results LIVE Updates:  IOC slips into loss; Maruti Suzuki profit beats estimates** — Q1 Results LIVE Updates: Four Nifty companies, ITC, Maruti Suzuki, Sun Pharma and Bajaj Finserv report results today to round off this week dominated by earnings. Broader market names like Dixon Tech, Indian Oil, Glenmark Pharma, GMDC, ABB India, SJVN, GAIL and NALCO among many others will also be reporting their results. The big result reactions of the day include the likes of Swiggy, Mazagon Dock, Thermax, Bajaj Finance's earnings call and upgrades among others. — [Source](https://www.cnbctv18.com/market/q1-results-live-updates-sun-pharma-itc-maruti-suzuki-bajaj-finserv-tata-steel-swiggy-share-price-liveblog-19958383.htm)
- 2026-07-27 — Mint: **How three stubborn men, and $1.5 billion poured in over two decades, put India on the world’s new-drug map | Mint** — While others made money producing generics by copying foreign discoveries, they bet on drug discovery in India, selling the family silver to fund their dreams. Now, after decades, they are seeing a payoff or within kissing distance of one. — [Source](https://www.livemint.com/industry/india-drug-discovery-big-pharma-generics-innovation-11785148249277.html)
- 2026-07-23 — CNBC-TV18: **Why Indian pharma stocks aren't panicking yet over Trump's proposed tariffs on generic drugs** — Indian drugmakers supply about 40% of the generic medicines imported by the US, making Trump's proposed tariffs a major risk. But a delayed rollout, existing US factories and other factors are keeping investors from hitting the panic button. — [Source](https://www.cnbctv18.com/market/why-indian-pharma-stocks-are-not-panicking-over-trump-tariffs-19952485.htm)
- 2026-07-22 — Economic Times: **Trump’s 100% generic drug duty threatens US low-cost supply** — President Donald Trump has given generic drugmakers two years to shift manufacturing to the US or face 100% import tariffs from August 2028, rising to 200% a year later. The move threatens India's pharmaceutical exports, could disrupt low-cost medicine supplies, raise drug prices, and trigger shortages for millions of American patients. — [Source](https://economictimes.indiatimes.com/news/economy/foreign-trade/trumps-100-generic-drug-duty-threatens-us-low-cost-supply/articleshow/132553340.cms)
- 2026-07-22 — News18: **Lupin, Aurobindo, Cipla Fall Up To 2.9%: Pharma Stocks Under Pressure As Trump's Tariff Roadmap Rattles Sentiment** — Lupin falls 2.88%, Aurobindo Pharma declines 2.73%, Alkem Laboratories slips 2.44%, Zydus Lifesciences drops 2.20%, while Cipla slips 2.09%. — [Source](https://www.news18.com/business/markets/lupin-aurobindo-cipla-fall-up-to-2-9-pharma-stocks-under-pressure-as-trumps-tariff-roadmap-rattles-sentiment-ws-l-10226502.html)
- 2026-07-22 — News18: **Dr Reddy, Aurobindo, Cipla: Pharma Stocks To Remain In Focus Today After Trump's New Generic Drugs Tariff Plan** — Imported generic medicines will remain tariff-free for two years from August 1, after which the US plans to impose a 100% duty for one year and a 200% tariff thereafter. — [Source](https://www.news18.com/business/markets/dr-reddy-aurobindo-cipla-pharma-stocks-to-remain-in-focus-today-after-trumps-new-generic-drugs-tariff-plan-ws-l-10226357.html)

## Business profile

**Strategic vision:** Global pharmaceutical company advancing science-led therapies.

### Business segments
- **Oncology:** Glenmark's Oncology portfolio concentrates on advancing therapies for solid tumors and hematological malignancies, leveraging deep disease understanding and global collaborations.
- **Respiratory:** In the Respiratory segment, Glenmark addresses chronic conditions like asthma, COPD, and common ailments, offering advanced devices and therapies.
- **Dermatology:** Dermatology is a foundational and strategically important therapeutic area with over four decades of research and more than 120 products.

### Competitive strengths
- Decades of research in dermatology
- Expertise in biologics discovery and early development within oncology
- Established portfolio of over 120 dermatological products

## Related stocks

- [ABBOTINDIA (Healthcare)](https://faxioms.com/stocks/abbotindia) — +5.50%
- [ACUTAAS (Healthcare)](https://faxioms.com/stocks/acutaas) — +3.86%
- [AJANTPHARM (Healthcare)](https://faxioms.com/stocks/ajantpharm) — +1.61%
- [ALKEM (Healthcare)](https://faxioms.com/stocks/alkem) — +0.14%
- [ANTHEM (Healthcare)](https://faxioms.com/stocks/anthem) — -0.35%

## Freshness and sources

- Data as of: 2026-09-18
- Source: Faxioms public stock analysis API

Canonical: https://faxioms.com/stocks/glenmark
Markdown representation: https://faxioms.com/stocks/glenmark?render=md